

UK is testbed for mass vaccination with gene therapies, leading to global rollout

HEDLEY REES—The Office for Life Sciences were hugely impressed by the potential for gene therapies manufactured by OXB in the UK, especially when OXB signed a £100 million agreement with Novartis to supply the viral vector for Kymriah (which they were developing while I was there):